KRAS and thyroid gland carcinoma: Anaplastic Thyroid carcinoma is an extremely aggressive solid tumor that resists most treatments and is almost always fatal.3,32 Gal-3 serves as a diagnostic marker to differentiate between benign and malignant human thyroid cancers,33 and the role of Ras in these tumors is also well documented.23 As Gal-3 was reported to act as a specific binding partner of activated K-Ras and that this interaction promotes K-Ras activation,5 we addressed the possible usage of these targets for a possible therapeutic modality against anaplastic thyroid carcinoma.